• Explore /
  • Poster
  • / Mutations within the EGFR signaling pathway: Influence on efficacy in FIRE-3—A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients.

Mutations within the EGFR signaling pathway: Influence on efficacy in FIRE-3—A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients.

Abstract Poster

Authors

Sebastian Stintzing

Sebastian Stintzing

Department of Hematology and Oncology, Klinikum Grosshadern and Comprehensive Cancer Center, LMU Munich, Munich, Germany

Sebastian Stintzing , Andreas Jung , Lisa Rossius , Dominik Paul Modest , Ludwig Fischer von Weikersthal , Thomas Decker , Alexander Kiani , Salah-Eddin Al-Batran , Ursula Vehling-Kaiser , Tobias Heintges , Markus Moehler , Werner Scheithauer , Thomas Kirchner , Volker Heinemann

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session C: Cancers of the Colon and Rectum

Track

Cancers of the Colon, Rectum, and Anus

Sub Track

Translational Research

Citation

J Clin Oncol 32, 2014 (suppl 3; abstr 445)

DOI

10.1200/jco.2014.32.3_suppl.445

Abstract #

445

Poster Bd #

B8

Abstract Disclosures

Similar Posters

First Author: Yoshihito Ohhara

First Author: Sebastian Stintzing

First Author: Ann-Lii Cheng

First Author: Marlies Michl